FUL Reports Q2 2026 Earnings

B. Fuller (NYSE: FUL ) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you APIs.

For real-time access to our entire catalog, please visit for a consultation. B. 6% driven by a 3% increase in pricing, partially offset by lower volumes. The company announced its plan to acquire Advanced Medical Solutions (AMS) for approximately 715 million pounds, aiming to transform its portfolio towards higher growth, higher margin sectors.

1%. B. 90. B.

Fuller's footprint in the medical market, which is seen as a non-discretionary, high-growth sector with significant barriers to entry. Operationally, the company managed to maintain supply continuity despite petrochemical supply chain disruptions, attributing this to its global sourcing capabilities. 5 to 3 times within two years post-acquisition. Management reaffirmed its commitment to disciplined capital allocation and maintaining strong shareholder value creation, despite the temporary increase in leverage due to the AMS acquisition.

B. Fuller second quarter 2026 earnings conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session, and if you would like to ask a question during this time, please press star 1 on your telephone keypad.

I would now like to turn the conference over to Scott Jensen, Director of Investor Relations. You may begin. Scott Jensen, Director of Investor Relations Thank you, operator. B.

Fuller's second quarter 2026 investor conference call. Presenting today are Celeste Mastin, President and Chief Executive Officer, and John Corcoran, Executive Vice President and Chief Financial Officer. After our prepared remarks, we will have a question and answer session. Before we begin, let me remind everyone that our comments today will include references to certain non-GAAP financial measures.

These measures are supplemental to the results determined in accordance with GAAP. We believe that these measures are useful to investors in understanding our operating performance and to compare our performance with other companies. Reconciliation of non-GAAP measures to the nearest GAAP measure are included in our earnings release unless otherwise noted. Comments about revenue refer to organic revenue, and comments about EBITDA and profit margins refer to adjusted non-GAAP measures.

We will also be making forward-looking statements during this call. These statements are based on current expectations and assumptions that are subject to risks and uncertainties. com. During this call, we will be referencing information from our second quarter earnings release along with the press release related to our announced offer to acquire Advanced Medical Solutions.

I will now turn the call over to Celeste Mastin. Celeste Mastin, CEO and President Thank you, Scott, and welcome to today's call. We executed very well in the second quarter, delivering strong year-on-year revenue, EBITDA, and EPS growth with results above the midpoint of our EBITDA guidance range. Our global sourcing capabilities and swift pricing actions have enabled us to maintain supply continuity and reliably serve our customers through this market disruption.

These efforts, combined with our Quantum Leap restructuring initiative, have strengthened our competitive position, and we remain confident in our ability to deliver superior financial results. To start today's call, we'll cover our consolidated results for the second quarter. We will then spend time discussing our announced offer to acquire Advanced Medical Solutions, or AMS. AMS is a highly compelling strategic fit and represents a rare opportunity to advance our long-term strategic priorities.

B. Fuller, and given its durable demand trends, high regulatory-based entry barriers, and attractive margin profile, Advanced Medical Solutions has built an exceptional business as a differentiated formulator with an innovation-led platform and outstanding product suite, impressive R&D capabilities, and a global commercial footprint with supporting regulatory expertise. The transaction is expected to result in significant revenue and cost synergies and accelerate our transformation into a higher growth, higher margin business.

We remain committed to disciplined and balanced capital allocation and believe that the continued uptiering of our portfolio, as well as the other steps we're taking to improve our cost structure and cash flow profile, will allow for robust deal deleveraging post-acquisition. We look forward to walking you through more details later in the call. 8% year-on-year, adjusting for foreign exchange and acquisitions. 6%, driven by p